The omnipresence of pink during awareness campaigns can function as an involuntary cue for trauma recall, reactivating uncertainty, grief, and embodied memories tied to cancer care. Survivorship is ...
Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...
FDA cleared BRAVNETSA for adult SSTR+ GEP-NETs spanning foregut, midgut, and hindgut sites, adding a second approved lutetium Lu 177 dotatate radiopharmaceutical option. ANDA-based approval ...
Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
For years, much of cancer research has focused on understanding the tumor itself — how cancer cells grow, what causes them to change and how those cells can be targeted with treatment. But researchers ...
Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology ...
After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, ...
After having cancer, travelling can become more than a getaway. It can be part of your emotional recovery. Rest, joy, and ...
Regulatory indication requires an FDA-authorized ESR1 test, with Guardant360 CDx approved to select candidates for imlunestrant plus abemaciclib. Phase 3 EMBER-3 enrolled 874 post–aromatase inhibitor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results